Literature DB >> 25959108

Evaluation of accelerated corneal collagen cross-linking for the treatment of bullous keratopathy in eight dogs (10 eyes).

Frank Famose1.   

Abstract

OBJECTIVE: Bullous keratopathy (BK) is a serious corneal condition leading to impaired vision and ocular pain, due to chronic corneal edema and recurrent superficial ulceration. BK is refractory to conventional therapy. In human patients, corneal collagen cross-linking (CXL) has been used for the treatment of BK, and CXL treatment was recently described for canine patients. The aim of this study was to evaluate the clinical and pachymetric effects of accelerated CXL in dogs affected by BK. ANIMAL STUDIED: Eight dogs (10 eyes) with BK underwent accelerated CXL. PROCEDURES: CXL treatment comprised 30 min of riboflavin-dextran instillation, followed by 3 min of UVA irradiation at 30 mW/cm². Ocular pain, corneal edema, corneal ulceration, and pachymetry were evaluated 7, 14, 30, 90, and 180 days after treatment.
RESULTS: Corneal ulceration and ocular pain were resolved by 1 week after CXL treatment and did not recur during the 6-month follow-up period. Corneal edema improved in the first 3 months, but worsened from months 3 to 6. Corneal thickness initially decreased, but returned to baseline by 6 months post-CXL.
CONCLUSIONS: CXL is a useful treatment option for BK in dogs, despite the short-lasting effects on corneal thickness. Patient comfort improved rapidly after a single procedure, although CXL did not achieve resolution of corneal edema. Treatment protocols may be refined to produce more durable effects on corneal edema.
© 2015 American College of Veterinary Ophthalmologists.

Entities:  

Keywords:  accelerated cross-linking; bullous keratopathy; dogs; endothelial dystrophy; optical coherence tomography; pseudophakic bullous keratopathy

Year:  2015        PMID: 25959108     DOI: 10.1111/vop.12280

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  4 in total

1.  Diagnostic Ophthalmology.

Authors:  Lynne S Sandmeyer; Marina Leis; Bianca Bauer
Journal:  Can Vet J       Date:  2019-03       Impact factor: 1.008

2.  Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs.

Authors:  Jessica A Martinez; Franck Chiappini; Denis Barritault
Journal:  Vet Sci       Date:  2019-12-13

3.  Case Report: Successful Management of Refractory Keratomycosis in an Alpaca Using Penetrating Keratoplasty and Combination Antifungal Therapy (Caspofungin 0.5% and Terbinafine 1%).

Authors:  Braidee C Foote; Joe S Smith; Anna Catherine Bowden; Rachel A Allbaugh; Lionel Sebbag
Journal:  Front Vet Sci       Date:  2021-03-11

4.  Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca.

Authors:  Simona Destefanis; Daniela Giretto; Maria Cristina Muscolo; Alessandro Di Cerbo; Gianandrea Guidetti; Sergio Canello; Angela Giovazzino; Sara Centenaro; Giuseppe Terrazzano
Journal:  BMC Vet Res       Date:  2016-09-22       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.